DNRS 6501 Week 8 Journal Club Critique Example

Course	DNRS 6501 Advanced Pathophysiology (DNP level)
Week	Week 8
Paper type	Journal club article critique
Length	About 860 words, 6 pages
Format	APA 7 student paper
School	Walden University
Program	Doctor of Nursing Practice (DNP)
Updated	October 2026

Free sample paper for DNRS 6501 Week 8

Article Critique: What CANTOS Proved About Inflammation in Atherothrombosis, and What It Was Said to Prove

Student Name

College of Nursing, Walden University

DNRS 6501: Advanced Pathophysiology (DNP level)

Instructor Name

Month Day, Year

What this page is doingThe title separates the trial's result from the claims built on it. That distinction is the critique's whole subject, so it belongs in the first line.

Article Critique: What CANTOS Proved About Inflammation in Atherothrombosis, and What It Was Said to Prove

Article critiqued: Ridker, P. M., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119-1131. This critique assumes the reader has the article open.

What Would Change If the Article Held

For decades, the pathophysiology of atherothrombosis taught that inflammation participates in plaque growth and rupture, but the evidence was associative: markers such as C-reactive protein predicted events, and lipid-lowering drugs that also reduced inflammation reduced events. No trial had lowered inflammation without lowering lipids and shown fewer events. If CANTOS holds, inflammation moves from a marker that travels with atherosclerosis to a cause that can be treated separately from cholesterol. That is the stake, and it is why the trial's claims deserve close reading.

What this page is doingOpening on what the article would change tells the reader why the next pages matter. A critique that begins with a summary of the study would spend its best position on description.

The Inference Past the Data

The most consequential problem is the distance between the result and the conclusion drawn around it. The trial tested one pathway, interleukin-1 beta, with one drug at three doses. The 150 mg dose reduced the primary end point with a hazard ratio of 0.85, and its 95% confidence interval reached 0.98. The 300 mg dose had a similar hazard ratio but did not meet the prespecified multiplicity threshold, and the 50 mg dose did not reduce events. There was no gradient between the two higher doses, 3.86 and 3.90 events per 100 person-years, although the 300 mg dose lowered C-reactive protein further (Ridker et al., 2017). A result carried by one of three doses, with no dose-response at the top, supports the statement that this pathway matters. It supports less well the broader statement, often made after the trial, that the inflammation hypothesis of atherothrombosis had been proven.

There is also a mechanistic gap the trial could not close. Interleukin-1 beta could act on plaque growth over years, on plaque rupture, or on the thrombotic response after rupture. An events trial lasting a median of 3.7 years cannot say which, and the discussion's language about inflammation driving atherothrombosis covers all three without evidence that separates them.

The Population the Sample Can Speak For

Enrollment required a previous myocardial infarction and a high-sensitivity C-reactive protein of at least 2 mg/L. That is a population selected for residual inflammatory risk. The result says nothing directly about patients with lower C-reactive protein, about people without established disease, or about stroke or peripheral disease as primary conditions. Enrichment was a reasonable design choice for proving a mechanism, but it limits how far the finding can be carried into practice.

The gap matters because the finding was quickly repeated in teaching as a general statement about atherosclerosis. A clinician applying it to an older adult with stable disease and a C-reactive protein of 1 mg/L would be relying on the mechanism, not on the trial.

The Measurement Chosen

C-reactive protein served as both the entry criterion and the evidence that the drug reduced inflammation. It is a hepatic product downstream of interleukin-6, so a fall in C-reactive protein shows that the pathway was affected but does not show that C-reactive protein itself matters. The primary end point was a composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. All-cause mortality did not differ, and fatal infections were more frequent with canakinumab (Ridker et al., 2017). The composite answers the mechanistic question; it does not answer the clinical question of net benefit.

What this page is doingThe three critical moves run from most to least consequential, not in the article's order. That keeps the reader's attention where the critique matters most.

A Defense Against an Unfair Objection

A common objection is that the benefit, roughly a 15% relative reduction, is too small to matter. For the question the trial was designed to answer, that objection misses the point. The trial's design held lipids constant; canakinumab did not lower lipid levels from baseline. Any reduction in events therefore came from something other than cholesterol, and a modest effect is exactly what would be expected when one inflammatory pathway is blocked on top of standard care. As a test of mechanism, the size of the effect matters less than its independence from lipids.

What this page is doingThe defense comes after the criticism, late enough to read as fairness rather than softening. It shows the writer can tell a weak objection from a strong one.

What the Comparison Trials Add

Two later trials sharpen the reading. In CIRT, low-dose methotrexate given to patients with coronary disease and diabetes or metabolic syndrome did not reduce interleukin-1 beta, interleukin-6, or C-reactive protein, and did not reduce events (Ridker et al., 2019). The result is consistent with CANTOS rather than contradicting it: where the pathway was not affected, events did not fall. In COLCOT, colchicine given within 30 days of myocardial infarction reduced a composite of ischemic events, with a hazard ratio of 0.77, largely through fewer strokes and urgent revascularizations (Tardif et al., 2019). A different drug acting on inflammation produced a similar direction of effect, which strengthens the causal reading more than CANTOS could alone.

The Claim That Survives

In patients with a previous myocardial infarction and a C-reactive protein of 2 mg/L or higher, blocking interleukin-1 beta with canakinumab 150 mg every 3 months reduced recurrent cardiovascular events without lowering lipids.

Everything beyond that sentence, including the general proof of the inflammation hypothesis, depends on the comparison trials and on work still under way, not on this article alone.

References

Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., Gupta, M., Tsigoulis, M., Verma, S., Clearfield, M., Libby, P., Goldhaber, S. Z., Seagle, R., Ofori, C., Saklayen, M., . . . Glynn, R. J. (2019). Low-dose methotrexate for the prevention of atherosclerotic events. The New England Journal of Medicine, 380(8), 752-762. https://doi.org/10.1056/NEJMoa1809798

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., . . . Glynn, R. J. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119-1131. https://doi.org/10.1056/NEJMoa1707914

Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., . . . Roubille, F. (2019). Efficacy and safety of low-dose colchicine after myocardial infarction. The New England Journal of Medicine, 381(26), 2497-2505. https://doi.org/10.1056/NEJMoa1912388

The Walden DNRS 6501 Week 8 instructions

The eighth week often asks for a critique of a recent article linking a pathophysiological mechanism to clinical outcomes, presented as a written journal club piece. The prompt usually expects you to evaluate the research question, design, sample, measures and conclusions, and to decide how far the findings can be applied. In some DNRS 6501 sections a live or recorded discussion goes with it. A summary is rarely wanted beyond a few lines, since the reader is assumed to know the study. Plan on an APA 7 paper of several pages that cites the article and at least one comparison study. The best critiques take a position on the strength of the main claim and defend it fairly, including against objections the critic finds unconvincing. Instructors read for argument, not for coverage of every section.

How this DNRS 6501 Week 8 example is built

Roughly three pages, written on the assumption that every reader has the article open. Nothing is summarized for its own sake: the study appears only in fragments, each pulled forward because the critique is about to do something with it. The opening paragraph states what the article would change about understanding if it held, which gives the critique its stakes. Three critical moves follow, each a paragraph, addressing the measurement chosen, the population the sample can speak for, and the inference the discussion makes past its own data. One paragraph defends the study against an objection a reader might raise unfairly. Two comparison studies are cited briefly. The close states which claim from the article survives intact.

Where the marks sit in the DNRS 6501 Week 8 rubric

Critique assignments separate cleanly into those that argue and those that report, and the reporting ones cluster mid-band no matter how well written. Credit follows whether each objection is specific enough that the authors could answer it, since a complaint about a small sample with no account of what the sample cannot reach is a sentence with no target. Sections read for whether the writer told a limitation the authors acknowledged apart from one they did not, because only the second is a finding. The defense paragraph is often worth more than its length suggests, as it demonstrates the article was read rather than mined. Endocrine mechanism studies invite overreach in their discussion sections, and a critique missing that overreach has left the most available points on the page.

Common DNRS 6501 Week 8 mistakes, and how to avoid them

Critiques usually lose marks by retelling the study section by section and adding a list of limitations copied from the discussion. Choose the two or three problems that change what the trial can claim and develop those. Students also treat every limitation as fatal, which is not credible; say which ones matter and which do not. Another common mistake is critiquing the mechanism the authors proposed without checking whether the endpoint chosen could test it. Do not ignore the comparison trials, since agreement or conflict between them is real evidence. Keep the critique fair by answering at least one objection that goes too far. Watch the numbers: report hazard ratios and absolute risks exactly as published. Finally, close with the claim you think survives scrutiny.

Get a DNRS 6501 Week 8 example written to your instructions

Forward the article, the critique prompt, and whether a presentation accompanies the paper, and a critique written for colleagues who already know the study comes back to you. The first custom one is free and returns inside 24 to 48 hours. Unpublished results from a study at your site belong to that study and are not written about here.

More DNRS 6501 papers and DNP samples

DNRS 6501 Week 8 questions, answered

Does a journal club critique need a summary section?

Usually not, and adding one is the most common way these papers lose room for judgment. The genre assumes a shared reading. Where a rubric explicitly asks for a brief overview, a short paragraph satisfies it, but the balance should still fall heavily toward what the study can and cannot support.

Should the critique be negative overall?

No. The strongest critiques often conclude that a study holds for a narrower claim than it advertises, which is a positive finding stated precisely. Sections tend to reward calibration over severity. A paper listing every conceivable flaw reads as a checklist, and it rarely says which flaw would change what a reader does.

Is there usually a presentation with this?

Some doctoral sections pair a written critique with a short recorded or live presentation, and others keep it written. Walden does not publish which weeks carry which format. If a presentation is attached to your prompt, the three critical moves become three slides, and the defense paragraph becomes the answer prepared for the first question.

Where can I find a free DNRS 6501 Week 8 sample paper?

This page carries the full CANTOS critique, from what would change if the trial held to the claim that survives, with margin notes on how each section argues.

What did CANTOS show in the DNRS 6501 Week 8 example?

The critique accepts that lowering interleukin 1 beta reduced recurrent cardiovascular events modestly, but argues the trial did not prove inflammation drives atherothrombosis in every patient or justify routine use.